Targets for Cancer Pain

Understanding the molecular targets involved in cancer pain is critical for elucidating the underlying pathogenic mechanisms, identifying effective therapeutic strategies, and supporting the development of novel analgesics. Cancer pain is a complex phenomenon resulting from tumor invasion, inflammation, nerve injury, and the interplay of multiple signaling pathways. The molecular targets highlighted—including opioid and cannabinoid receptors, prostaglandin synthases, nerve growth factor, voltage-gated sodium channels, and relevant transporters—represent key nodes in nociceptive, inflammatory, and neuropathic pain pathways. Collectively, these targets provide insight into how cancer induces pain via direct tumor-nerve interactions, inflammatory mediators, and neural sensitization. Targeting these molecules enables the development of more precise analgesics, reduces reliance on opioids, and addresses pain that is refractory to standard therapies. Furthermore, understanding these targets supports biomarker discovery, patient stratification, and the development of personalized pain management strategies in oncology.

Opioid Receptor-Mediated Nociception

This category includes targets that are classical opioid receptors directly mediating analgesia and modulating nociceptive transmission in cancer pain. These receptors are central to the pharmacological management of moderate to severe cancer pain, and their dysregulation or altered expression can impact analgesic efficacy and the development of opioid tolerance or hyperalgesia. The targets discussed are opioid receptor delta 1 (OPRD1), opioid receptor kappa 1 (OPRK1), and opioid receptor mu 1 (OPRM1).

Opioid Receptor Delta 1 (OPRD1)

Opioid Receptor Delta 1 (OPRD1) is a G protein-coupled receptor (GPCR) with seven transmembrane domains, primarily expressed in the central and peripheral nervous systems. OPRD1 modulates nociceptive signaling via inhibition of adenylate cyclase, reducing cAMP levels and neuronal excitability. In cancer pain, OPRD1 is implicated in modulating both acute and chronic pain states, with evidence showing upregulation in response to persistent nociceptive stimuli. OPRD1 interacts with endogenous enkephalins and exogenous opioids, contributing to analgesia but also influencing tolerance development. Its pathogenic role is supported by animal models where delta agonists attenuate cancer-induced hyperalgesia. Therapeutically, selective delta agonists are under investigation for their analgesic potential with reduced side effects compared to mu agonists. OPRD1 is also a candidate biomarker for opioid responsiveness.

Opioid Receptor Kappa 1 (OPRK1)

Opioid Receptor Kappa 1 (OPRK1) is a GPCR with a canonical seven-transmembrane structure, predominantly expressed in the dorsal horn of the spinal cord and certain brain regions. OPRK1 activation inhibits neurotransmitter release via Gi/o protein signaling, decreasing neuronal excitability. In the context of cancer pain, OPRK1 is involved in modulating visceral and neuropathic pain components, and its activation produces analgesia with a different side effect profile compared to mu agonists. Kappa agonists have shown efficacy in preclinical models of bone cancer pain. However, dysphoric and psychotomimetic effects limit clinical use. OPRK1 is regulated by phosphorylation, receptor internalization, and desensitization mechanisms. Its role as a therapeutic target is being explored for opioid-sparing strategies.

Opioid Receptor Mu 1 (OPRM1)

Opioid Receptor Mu 1 (OPRM1) is the principal target for most clinically used opioids. It is a GPCR with seven transmembrane domains, widely distributed in pain pathways. OPRM1 mediates analgesia by inhibiting presynaptic neurotransmitter release and postsynaptic neuronal firing. In cancer pain, OPRM1 expression and function can be altered by chronic opioid exposure, inflammation, and tumor-derived factors. Polymorphisms in OPRM1 (e.g., A118G) influence opioid efficacy and individual variability in pain control. OPRM1 is tightly regulated by phosphorylation, β-arrestin recruitment, and receptor trafficking. All clinically approved strong opioids (e.g., morphine, fentanyl) act primarily through OPRM1. Its role as a biomarker for opioid responsiveness and tolerance is well established, and it remains the cornerstone for severe cancer pain management.

Cannabinoid And Related Gpcr Modulation

This category includes cannabinoid receptors (CNR1, CNR2) and the orphan G protein-coupled receptor GPR55, all of which are implicated in the modulation of nociceptive and inflammatory pain in cancer. These targets are involved in both central and peripheral pain pathways and are of growing interest for non-opioid pain management.

Cannabinoid Receptor 1 (CNR1)

Cannabinoid Receptor 1 (CNR1) is a GPCR highly expressed in the central nervous system, particularly in pain-processing regions. Structurally, it has seven transmembrane domains and couples to Gi/o proteins, inhibiting adenylate cyclase and modulating neurotransmitter release. CNR1 modulates both nociceptive and affective components of pain. In cancer pain models, CNR1 agonists reduce hyperalgesia and allodynia, and endogenous cannabinoids are upregulated in response to tumor-induced inflammation. CNR1 is regulated by ligand-induced desensitization and internalization. Therapeutically, CNR1 agonists (e.g., dronabinol) and modulators are under clinical investigation for cancer pain, offering opioid-sparing effects. Clinical evidence supports moderate efficacy, particularly in neuropathic and refractory cancer pain.

Cannabinoid Receptor 2 (CNR2)

Cannabinoid Receptor 2 (CNR2) is a GPCR predominantly expressed in immune cells and peripheral tissues, with upregulation in inflamed and tumorous environments. Like CNR1, it has seven transmembrane domains and signals via Gi/o proteins. CNR2 modulates immune cell migration, cytokine release, and inflammatory pain. In cancer pain, CNR2 activation suppresses proinflammatory cytokine production and reduces tumor-induced nociception in preclinical models. CNR2 expression is increased in cancer-associated neuropathy. Selective CNR2 agonists are being studied to provide analgesia without central psychoactive effects. CNR2 is a promising target for peripheral modulation of cancer pain.

G Protein-Coupled Receptor 55 (GPR55)

G Protein-Coupled Receptor 55 (GPR55) is an orphan GPCR structurally related to cannabinoid receptors, with seven transmembrane domains and broad tissue distribution. GPR55 is activated by lysophosphatidylinositol and certain cannabinoids. In cancer pain, GPR55 modulates neuronal excitability and inflammatory signaling, with evidence of upregulation in cancer-infiltrated tissues and involvement in mechanical hyperalgesia. GPR55 antagonists reduce pain in preclinical cancer models. Regulation occurs via phosphorylation and β-arrestin pathways. GPR55 is a novel target for non-opioid analgesic development.

Prostaglandin-Mediated Inflammatory Pathways

This category encompasses cyclooxygenase (COX) enzymes responsible for prostaglandin synthesis, which play a central role in mediating inflammation and peripheral sensitization in cancer pain. Prostaglandin-endoperoxide synthase 1 (PTGS1) and prostaglandin-endoperoxide synthase 2 (PTGS2) are included.

Prostaglandin-Endoperoxide Synthase 1 (PTGS1)

Prostaglandin-Endoperoxide Synthase 1 (PTGS1), also known as COX-1, is a constitutively expressed enzyme with peroxidase and cyclooxygenase domains. It catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor of various prostanoids. In cancer pain, PTGS1-derived prostaglandins contribute to peripheral and central sensitization, particularly in tumor-induced inflammation. Although COX-1 is less inducible than COX-2, its activity sustains basal prostaglandin levels that can exacerbate pain in the tumor microenvironment. Inhibition of PTGS1 by nonsteroidal anti-inflammatory drugs (NSAIDs) reduces pain but may cause gastrointestinal side effects. PTGS1 is a validated target for adjuvant analgesia in cancer pain.

Prostaglandin-Endoperoxide Synthase 2 (PTGS2)

Prostaglandin-Endoperoxide Synthase 2 (PTGS2), or COX-2, is an inducible enzyme with cyclooxygenase and peroxidase domains, upregulated in response to inflammatory cytokines, growth factors, and tumor invasion. PTGS2 is overexpressed in many cancers and at sites of tumor-nerve interaction, driving increased prostaglandin E2 (PGE2) production and sensitization of nociceptors. PTGS2-mediated prostaglandin release is a major contributor to cancer-induced inflammatory pain and hyperalgesia. Selective COX-2 inhibitors (e.g., celecoxib) provide analgesic benefit in cancer pain with a reduced gastrointestinal risk profile. PTGS2 expression correlates with pain severity in clinical studies, supporting its role as a biomarker and therapeutic target.

Neurotrophic And Inflammatory Mediators

This category is represented by nerve growth factor (NGF), a neurotrophin that mediates cancer pain by promoting neuronal sensitization, sprouting, and inflammatory signaling. NGF is a key driver of both inflammatory and neuropathic pain in cancer.

Nerve Growth Factor (NGF)

Nerve Growth Factor (NGF) is a secreted neurotrophin with a cystine-knot structure, essential for the survival and function of nociceptive neurons. NGF binds to TrkA and p75NTR receptors, activating downstream MAPK, PI3K, and PLCγ pathways. In cancer, NGF is overexpressed by tumor and stromal cells, leading to increased nerve fiber density, sensitization, and pain. NGF also stimulates the release of inflammatory mediators and upregulates ion channels involved in nociception. Neutralizing antibodies against NGF (e.g., tanezumab) have demonstrated efficacy in reducing cancer pain in clinical trials. NGF is a validated therapeutic target and biomarker for cancer pain severity.

Voltage-Gated Sodium Channel-Mediated Neuronal Excitability

This category includes sodium voltage-gated channel alpha subunit 9 (SCN9A), which encodes Nav1.7, a key channel in nociceptive neurons. Nav1.7 is upregulated and sensitized in cancer pain, contributing to neuronal hyperexcitability and spontaneous pain.

Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A)

Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) encodes the Nav1.7 channel, a voltage-gated sodium channel with four homologous domains, each containing six transmembrane segments. Nav1.7 is highly expressed in peripheral nociceptors. In cancer pain, SCN9A is upregulated by tumor-derived factors and inflammatory cytokines, increasing neuronal excitability and spontaneous firing. SCN9A mutations are associated with pain disorders, and its inhibition reduces pain in preclinical cancer models. Selective Nav1.7 blockers are in development for cancer and neuropathic pain. SCN9A is a promising target for non-opioid analgesics and may serve as a biomarker for pain severity and treatment response.